We are live on
!
Find out more
Adage Capital Partners Portfolio holdings
AUM
$64.8B
1-Year Est. Return
42.7%
This Fund
S&P 500
This Quarter
Est. Return
+9.95%
1 Year Est. Return
+42.7%
3 Year Est. Return
+139.29%
5 Year Est. Return
+204.38%
10 Year Est. Return
+829.83%
AUM
$39.9B
AUM Growth
+$891M
(+2.3%)
Cap. Flow
-$1.96B
Cap. Flow
% of AUM
-4.91%
Top 10 Holdings %
Top 10 Hldgs %
26.01%
Holding
846
New
122
Increased
198
Reduced
391
Closed
98
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Johnson & Johnson
JNJ
|
+$171M |
| 2 |
Sensata Technologies
ST
|
+$145M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$133M |
| 4 |
Amazon
AMZN
|
+$67.2M |
| 5 |
AbbVie
ABBV
|
+$65.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Otis Worldwide
OTIS
|
+$164M |
| 2 |
Ross Stores
ROST
|
+$110M |
| 3 |
Bank of America
BAC
|
+$94.4M |
| 4 |
Freeport-McMoran
FCX
|
+$92.4M |
| 5 |
Five Below
FIVE
|
+$89.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 23.1% |
| 2 | Healthcare | 19.47% |
| 3 | Consumer Discretionary | 12.58% |
| 4 | Financials | 11.29% |
| 5 | Communication Services | 8.51% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
176
Jabil
JBL
$35.5B
| $50.6M | 0.13% |
1,477,086
-232,712
| -14% | -$7.78M |
|
177
Biogen
BIIB
$30.5B
| $50.2M | 0.13% |
176,880
+121,290
| +218% | +$33.8M |
|
|
CMA
178
DELISTED
Comerica
CMA
| $50.2M | 0.13% |
1,311,212
+174,296
| +15% | +$6.7M |
|
179
CACI
CACI
$11.4B
| $50M | 0.13% |
234,787
+179,787
| +327% | +$38.9M |
|
180
Eli Lilly
LLY
$1.04T
| $49.4M | 0.12% |
333,851
+121,200
| +57% | +$18.8M |
|
181
Protagonist Therapeutics
PTGX
$8.83B
| $49.3M | 0.12% |
2,520,600
+320,600
| +15% | +$6.02M |
|
182
Republic Services
RSG
$63.7B
| $49.2M | 0.12% |
526,570
+80,137
| +18% | +$7.17M |
|
|
IPG
183
DELISTED
Interpublic Group of Companies
IPG
| $48M | 0.12% |
2,882,340
+2,481,569
| +619% | +$44.3M |
|
184
Hartford Financial Services
HIG
$39.4B
| $47.7M | 0.12% |
1,294,483
+407,000
| +46% | +$16.2M |
|
185
Karyopharm Therapeutics
KPTI
$43.3M
| $46.9M | 0.12% |
214,195
-2,388
| -1% | -$584K |
|
186
US Bancorp
USB
$100B
| $46.8M | 0.12% |
1,304,100
-129,700
| -9% | -$4.75M |
|
187
Northrop Grumman
NOC
$79.2B
| $46.5M | 0.12% |
147,243
+72,017
| +96% | +$23.5M |
|
|
GRMN
188
Garmin
GRMN
$58.3B
| $46.4M | 0.12% |
489,012
-57,107
| -10% | -$5.71M |
|
189
Pinnacle West Capital
PNW
$12.3B
| $46.3M | 0.12% |
621,063
+96,000
| +18% | +$7.35M |
|
190
Kura Oncology
KURA
$817M
| $46M | 0.12% |
1,500,450
-309,000
| -17% | -$6.82M |
|
191
Immunovant
IMVT
$8.06B
| $45.9M | 0.12% |
1,305,000
-1,061,062
| -45% | -$31.9M |
|
192
DuPont de Nemours
DD
$19.9B
| $45.5M | 0.11% |
653,151
-25,175
| -4% | -$1.76M |
|
193
SLB Ltd
SLB
$74.1B
| $45.5M | 0.11% |
2,922,867
+962,800
| +49% | +$17.9M |
|
194
Baxter International
BAX
$14.1B
| $45.4M | 0.11% |
564,252
-465,100
| -45% | -$39.1M |
|
195
Cameco
CCJ
$41.1B
| $45.3M | 0.11% |
4,486,089
-4,250,000
| -49% | -$46M |
|
196
Parker-Hannifin
PH
$126B
| $45.2M | 0.11% |
+223,420
| New | +$44M |
|
197
Gen Digital
GEN
$16.7B
| $45.1M | 0.11% |
2,166,216
+28,600
| +1% | +$619K |
|
|
FLG
198
Flagstar Bank National Association
FLG
$5.96B
| $45M | 0.11% |
1,814,964
+728,098
| +67% | +$20.8M |
|
199
Olin
OLN
$2.13B
| $44.8M | 0.11% |
3,619,782
-2,200,000
| -38% | -$25.4M |
|
200
DexCom
DXCM
$31.2B
| $44.2M | 0.11% |
428,676
+1,600
| +0.4% | +$167K |
|
Similar funds
Adage Capital Partners's Q3 2020 Portfolio in Review
As of Q3 2020, Adage Capital Partners held 846 positions worth $39.9B, up 2.3% from $39.1B the previous quarter. Its ten largest holdings account for 26% of the portfolio.
Adage Capital Partners withdrew a net $1.96B in Q3 2020, closing 98 positions and reducing 391 holdings. Its most notable exit was Pfizer, an estimated $60.9M position sold in full.
By sector, the portfolio is most concentrated in Technology at 23% of assets, up from 22% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, Adage Capital Partners opened a new position in Bristol-Myers Squibb worth $134M.
- Adage Capital Partners's largest Q3 2020 buy was Bristol-Myers Squibb: 2,215,804 shares worth $134M.
- Adage Capital Partners added most to Johnson & Johnson in Q3 2020, an estimated $171M increase.
- Adage Capital Partners's biggest Q3 2020 reduction was Otis Worldwide, cutting an estimated $164M.
- Adage Capital Partners fully exited Pfizer in Q3 2020, selling an estimated $60.9M.
- Adage Capital Partners's ten largest holdings make up 26% of its $39.9B portfolio in Q3 2020.
- Adage Capital Partners opened 122 new positions and closed 98 in Q3 2020.
- Adage Capital Partners's portfolio value rose 2.3% quarter-over-quarter to $39.9B.
Based on Adage Capital Partners's 13F filing for Q3 2020, filed 16 Nov 2020.